The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis
Home »
Publications » The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis
Publish Date 06/06/2024
Category
Keywords
The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis
Join the Arbor Assays Newsletter
Sign up for Arbor Assays’ email list to stay up to date on special deals, new kits, and published articles featuring Arbor Assays’ products
